Interestingly, recent studies proposed that DNA methylation-based pattern change was associated with PD-L1 expression and TMB, which may serve as a predictive biomarker to select lung cancer patients with a clinical response to ICI therapy (23, 26). Here, CD274 is linked to lung carcinoma.